Roth Capital reaffirmed their buy rating on shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) in a report issued on Tuesday. They currently have a $520.00 price objective on the biopharmaceutical company’s stock.
A number of other analysts have also recently issued reports on REGN. Robert W. Baird reissued a neutral rating and issued a $448.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Friday, September 23rd. Vetr raised shares of Regeneron Pharmaceuticals from a buy rating to a strong-buy rating and set a $429.64 price objective for the company in a research note on Monday, June 13th. Goldman Sachs Group Inc. reissued a buy rating and issued a $521.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 27th. Sanford C. Bernstein reissued a buy rating on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 30th. Finally, Zacks Investment Research cut shares of Regeneron Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have given a buy rating to the stock. The company currently has a consensus rating of Hold and an average target price of $480.09.
Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 0.12% during mid-day trading on Tuesday, reaching $389.06. 68,710 shares of the company’s stock traded hands. The stock has a market capitalization of $40.71 billion, a PE ratio of 60.70 and a beta of 1.31. Regeneron Pharmaceuticals has a 12-month low of $329.09 and a 12-month high of $592.59. The stock has a 50-day moving average price of $402.41 and a 200-day moving average price of $391.71.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported $2.82 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.65 by $0.17. Regeneron Pharmaceuticals had a net margin of 15.65% and a return on equity of 23.77%. The business had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.24 billion. During the same period last year, the firm earned $2.89 earnings per share. The company’s quarterly revenue was up 21.4% on a year-over-year basis. Equities research analysts expect that Regeneron Pharmaceuticals will post $11.02 EPS for the current year.
In related news, Director Joseph L. Goldstein sold 2,125 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, July 29th. The shares were sold at an average price of $425.00, for a total transaction of $903,125.00. Following the completion of the sale, the director now owns 15,125 shares in the company, valued at approximately $6,428,125. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 10.40% of the company’s stock.
A number of large investors have recently made changes to their positions in REGN. IFP Advisors Inc raised its stake in shares of Regeneron Pharmaceuticals by 32.3% in the second quarter. IFP Advisors Inc now owns 328 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 80 shares during the last quarter. Advisory Services Network LLC raised its stake in shares of Regeneron Pharmaceuticals by 5,433.3% in the second quarter. Advisory Services Network LLC now owns 332 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 326 shares during the last quarter. Fuller & Thaler Asset Management Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth $140,000. Brave Asset Management Inc bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth $157,000. Finally, Bessemer Group Inc. raised its stake in shares of Regeneron Pharmaceuticals by 45.4% in the first quarter. Bessemer Group Inc. now owns 548 shares of the biopharmaceutical company’s stock worth $198,000 after buying an additional 171 shares during the last quarter. Institutional investors own 68.16% of the company’s stock.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.